Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Contract revenue	$ 507,171	$ 946,982	$ 1,644,818	$ 2,647,417
Grant revenue	101,640	307,922	393,835	1,297,238
Total revenues	608,811	1,254,904	2,038,653	3,944,655
Cost of revenues	(386,641)	(965,453)	(1,579,485)	(2,980,191)
Gross profit	222,170	289,451	459,168	964,464
Operating expenses:
Research and development	1,266,527	2,266,799	6,136,743	5,763,467
General and administrative	768,420	789,251	2,422,863	2,432,550
Research and development expense - milestone			5,000,000
Total operating expenses	2,034,947	3,056,050	13,559,606	8,196,017
Loss from operations	(1,812,777)	(2,766,599)	(13,100,438)	(7,231,553)
Foreign currency transaction gain/(loss)	(7,647)	8,809	(34,465)	11,479
Interest income	486	37,007	24,450	125,467
Research and development incentives	29,778		125,303
Net loss before income taxes	(1,790,160)	(2,720,783)	(12,985,150)	(7,094,607)
Income tax benefit			836,893	610,676
Net loss applicable to common stockholders	$ (1,790,160)	$ (2,720,783)	$ (12,148,257)	$ (6,483,931)
Basic and diluted net loss per share (in Dollars per share)	$ (0.06)	$ (0.14)	$ (0.45)	$ (0.34)
Basic and diluted weighted average common shares outstanding (in Shares)	29,572,392	20,094,930	26,639,116	18,877,657